IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC

Core Insights - IDEAYA Biosciences, Inc. is recognized as one of the 10 Fastest Growing NASDAQ Stocks to Buy [1] Group 1: Clinical Developments - On February 25, 2026, IDEAYA announced the enrollment of the first patient in its Phase 1 trial for IDE034, a bispecific ADC targeting PTK7/B7H3, with a focus on safety, tolerability, and pharmacokinetics [2] - The company plans to explore combinations of IDE034 with agents targeting the DNA damage response pathway, including its proprietary PARG inhibitor IDE161 [2] - The initiation of dosing for the first patient triggers a $5 million milestone payment from IDEAYA to Biocytogen as per their licensing agreement [2] Group 2: Leadership Changes - On February 23, 2026, IDEAYA appointed Theodora Ross as the chief development officer to lead early clinical development for the oncology pipeline and guide long-term R&D strategy [3] - Ross previously held the position of VP and head of early oncology R&D at AbbVie [3] Group 3: Financial Performance - IDEAYA reported Q4 revenue of $10.88 million, significantly exceeding consensus estimates of $5.95 million [4] - The revenue reflects collaboration performance obligations related to research and development services under the Servier exclusive license agreement for darovasertib [4] - President and CEO Yujiro Hata highlighted strong clinical execution, pipeline expansion, and commercial readiness activities, including the completion of enrollment of 437 patients in the OptimUM-02 Phase 2/3 trial [4]